Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Protalix BioTherapeutics's Revenue for the
three
months ended in Jun. 2026 was €17.27 Mil. Protalix BioTherapeutics's average Accounts Receivable for the
three
months ended in Jun. 2026 was €8.43 Mil.
Hence, Protalix BioTherapeutics's Receivables Turnover for the
three
months ended in Jun. 2026 was 2.05.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Protalix BioTherapeutics Receivables Turnover Related Terms
Protalix BioTherapeutics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Protalix BioTherapeutics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PBDA vs GLSI, DTIL, NERV: Receivables Turnover Comparison
For the Biotechnology subindustry, Protalix BioTherapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protalix BioTherapeutics Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Protalix BioTherapeutics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protalix BioTherapeutics (FRA:PBDA) has a Receivables Turnover of 2.05 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Protalix BioTherapeutics and its competitors. According to the industry distribution chart, Protalix BioTherapeutics ranks #269 out of 847 companies in the Biotechnology industry, placing it in the top 31.8%.
Is Protalix BioTherapeutics' Receivables Turnover too high?
Protalix BioTherapeutics' current Receivables Turnover is 2.05. The Biotechnology industry median Receivables Turnover is 5.27. Protalix BioTherapeutics' value of 2.05 is 61.1% below this industry median. Based on the distribution chart, Protalix BioTherapeutics ranks #269 out of 847 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Protalix BioTherapeutics has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Protalix BioTherapeutics' Receivables Turnover compare to GLSI and DTIL?
According to the Biotechnology industry distribution chart, Protalix BioTherapeutics ranks #269 out of 847 companies for Receivables Turnover. This puts Protalix BioTherapeutics in the upper half of its industry. The industry median Receivables Turnover is 5.27. Protalix BioTherapeutics' value of 2.05 is 61.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 847 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Protalix BioTherapeutics's current Receivables Turnover of 2.05 is 61.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Protalix BioTherapeutics and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Protalix BioTherapeutics's current Receivables Turnover is 2.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protalix BioTherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protalix BioTherapeutics (FRA:PBDA) is currently considered Fairly Valued. The stock's GF Value™ is €1.89, compared to a current price of €2.00 — trading 5.8% above its estimated fair value. The current Receivables Turnover is 2.05 and 61.1% below the Biotechnology industry median of 5.27. Protalix BioTherapeutics' overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Protalix BioTherapeutics (FRA:PBDA), the current Receivables Turnover is 2.05 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Protalix BioTherapeutics (FRA:PBDA) Overvalued in 2026?
Based on GuruFocus' analysis, Protalix BioTherapeutics stock appears to be overvalued.
The current stock price of €2.00 is trading 5.8% above its estimated GF Value™ of €1.89.
GuruFocus considers Protalix BioTherapeutics to be Fairly Valued.
Key valuation signals for FRA:PBDA:
Receivables Turnover: 2.05
GF Value™: €1.89 vs. price of €2.00 (5.8% above fair value)
Industry Position: 61.1% below the Biotechnology median (#269 of 847)
No single metric tells the full story. See the FRA:PBDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
56GF Score
Get the complete analysis for FRA:PBDA
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PBDA has been successfully added to your 
